Portfolio company
Adipo Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This biopharmaceutical company develops Notch-inhibiting nanoparticle therapies that convert white fat into energy-burning brown fat for patients with obesity and Type 2 diabetes.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
AdipoPharma
This clinical-stage biotechnology company develops therapeutic peptides to treat insulin resistance and type 2 diabetes for patients with metabolic disorders.
AdipoPharma SAS
This biotech company develops a therapeutic peptide to treat insulin resistance and type 2 diabetes for patients with metabolic diseases.
Antag Therapeutics
This company develops GIP receptor antagonist therapies to treat patients living with obesity, type 2 diabetes and metabolic disorders.
Moonwalk Biosciences
The company develops adipose-targeted RNA therapies to treat obesity and cardiometabolic diseases for patients requiring weight loss and lean mass preservation.
Fable Therapeutics
The company develops protein-engineered biologics using machine learning to treat patients with obesity and metabolic diseases.
Alveus Therapeutics
This clinical-stage biotechnology company develops next-generation therapies for obesity and metabolic diseases to provide sustained weight loss for patients.
Carmot Therapeutics
This biotechnology company develops drug therapies to treat metabolic diseases, such as obesity and diabetes, for patients with these conditions.
Ousia Pharma
This biotechnology company develops peptide-drug conjugates to treat obesity and cardiometabolic diseases for patients requiring improved metabolic health and weight regulation.